Aptorum Group Provides Update on DiamiR Biosciences Merger
Post-Merger company, Niki BioSolutions, Inc., to Trade on Nasdaq Under Ticker “NIKI”
GlobeNewsWire7/16/2026Neutral
APM
Aptorum Group Ltd Class ANASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
570,060
P/E Ratio
—
EPS
$-1.90
Beta
0.17
52W High
$12.24
52W Low
$0.65
50-Day MA
$8.62
200-Day MA
$10.16
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aptorum Group Ltd Class A
Aptorum Group Limited, a pharmaceutical company, is dedicated to the discovery, development and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 5,250 |
| EBITDA | $-1.56M |
| Operating Margin | 0.00% |
| Return on Equity | -10.80% |
| Return on Assets | -6.52% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $28.38 |
| Price-to-Book | 0.30 |
| Price-to-Sales (TTM) | 23.35 |
| EV/Revenue | 31.22 |
| EV/EBITDA | -0.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | 634,680 |
| Float | 535,930 |
| % Insiders | 16.41% |
| % Institutions | 2.47% |
Historical Volatility
HV 10-Day
90.33%
HV 20-Day
69.05%
HV 30-Day
98.16%
HV 60-Day
91.64%
HV Rank
—
Volatility is currently contracting
Latest News
Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer's Association International Conference (AAIC), taking place at the Excel London Convention & Exhibition Centre, in London, UK, and online, on July 11-15, 2026, showcasing biomarker technologies from DiamiR's CLIA-certified, CAP-accredited clinical laboratory. Alidad Mireskandari, Ph.D.
GlobeNewsWire7/8/2026Neutral
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs. and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a collaboration between DiamiR and AlzLabs Precision Diagnostics (“AlzLabs”) to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer's disease.
GlobeNewsWire6/22/2026Neutral
Statement in Response to Silver Elephant's News Release Dated June 17, 2026
Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Andean Precious Metals Corp. (TSX: APM) (OTCQX: ANPMF) ("Andean" or the "Company") is aware of the news release issued by Silver Elephant Mining Corp. ("Silver Elephant") on June 17, 2026, regarding its filing of a Notice of Civil Claim in Vancouver, British Columbia. The allegations contained in Silver Elephant's news release and its Notice of Civil Claim are spurious and wholly without merit, and Andean strongly disagrees with Silver Elephant's characterization of the facts and circumstances described therein.
Newsfile Corp6/18/2026Neutral
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
NEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced that at its shareholder meeting held on June 9, 2026, its shareholders voted to approve the proposed merger transaction with DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases.
GlobeNewsWire6/10/2026Neutral
Andean Precious Metals Corp. (APM:CA) Q1 2026 Earnings Call Transcript
Andean Precious Metals Corp. (APM:CA) Q1 2026 Earnings Call Transcript
Seeking Alpha5/13/2026Neutral
Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript
Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript
Seeking Alpha3/25/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on APM and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026